Sec15B Inhibitors
Chemical inhibitors of Sec15B disrupt various stages of vesicular trafficking and cytoskeletal dynamics, thereby impeding the protein's role in vesicle docking and fusion at the plasma membrane. Brefeldin A hampers vesicular transport by inhibiting the ARF1/COPI interaction, which is a process fundamental to the movement of vesicles from the ER to the Golgi apparatus. Similarly, Exo1 and Golgicide A target GBF1, a guanine nucleotide exchange factor (GEF) for ARF1, necessary for the vesicle formation from the ER. This inhibition leads to a reduction in vesicle trafficking, indirectly curtailing Sec15B's function in exocytosis. Dynasore and MiTMAB both target dynamin GTPase activity, which is critical for the release of clathrin-coated vesicles. By preventing vesicle scission, these inhibitors ultimately decrease the number of vesicles available for Sec15B to act upon, thereby reducing its function in vesicle targeting and fusion.
Further disruption of Sec15B's function is achieved by compounds such as Nocodazole and Cytochalasin D, which disintegrate microtubules and actin filaments, respectively. Such disintegration is detrimental to the delivery and movement of vesicles within the cell, crucial stages where Sec15B exerts its effect. Latrunculin B and Jasplakinolide affect actin dynamics differently; Latrunculin B binds to actin monomers and prevents their polymerization, whereas Jasplakinolide stabilizes the filaments, preventing their proper dynamics. Both actions result in impaired vesicle docking and fusion processes involving Sec15B. The inhibition of Cdc42 by ML141 also disrupts actin filament organization, affecting vesicle movement towards the plasma membrane. SecinH3 targets cytohesins, leading to compromised ARF GTPase activity which is essential in mediating vesicular transport and, by extension, Sec15B's role. Lastly, SMIFH2 inhibits formin-mediated actin nucleation, further disrupting the actin filament formation that is necessary for the proper localization and function of Sec15B in the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the ARF1/COPI interaction which is crucial for vesicular trafficking from the ER to the Golgi apparatus. Since Sec15B is a component of the exocyst complex involved in vesicular trafficking, Brefeldin A's action would impede vesicle docking and fusion events mediated by Sec15B. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is an inhibitor of the Sec7 domain of GBF1, a GEF for ARF1, which is essential for vesicle formation and trafficking. By inhibiting GBF1, Exo1 would consequently inhibit vesicular transport, thereby indirectly inhibiting Sec15B function in vesicle tethering and fusion. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits GBF1, a GEF for ARF1, which is involved in vesicle formation from the ER. Inhibition of GBF1 would lead to reduced vesicle trafficking, thus indirectly inhibiting the role of Sec15B in exocytosis. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase required for the scission of clathrin-coated vesicles from the membrane. By blocking vesicle release, Sec15B's role in vesicle targeting and fusion to the membrane is indirectly inhibited. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules, which are necessary for vesicle transport within the cell. Disrupted microtubule dynamics would impede vesicle delivery to sites where Sec15B operates, thereby indirectly inhibiting its function. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin filaments, which are involved in vesicle movement and docking. This disruption can impede the delivery of vesicles to the plasma membrane, where Sec15B mediates tethering and fusion. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin B binds to actin monomers, preventing their polymerization. The resulting actin depolymerization would impede vesicle docking and fusion processes involving Sec15B. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their dynamics, which are essential for vesicle motility. Stabilized actin filaments would indirectly inhibit Sec15B function by disrupting vesicle transport. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 inhibitor; Cdc42 is a small GTPase involved in actin filament organization. By inhibiting Cdc42, ML141 would disrupt actin dynamics necessary for vesicle docking, indirectly inhibiting Sec15B. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 inhibits cytohesins, which are ARF GEFs, and are involved in vesicle trafficking. Inhibiting cytohesins would lead to compromised vesicle transport and indirect inhibition of Sec15B function. | ||||||